Mepolizumab: Which condition benefits more: Nasal polyps or eosinophilic asthma?
Our results showed that mepolizumab is an effective treatment option for eosinophilic severe asthma and CRSwNP in patients having both diseases. Before mepolizumab, most patients' quality of life was affected by asthma symptoms, but this changed, and their quality of life began to be affected primarily by CRSwNP symptoms. This suggests that mepolizumab treatment is more effective in suppressing asthma symptoms than suppressing nasal polyp symptoms.
Authors
- Murat Türk (ORCID: https://orcid.org/0000-0002-3290-2661)
- Elif Açar (ORCID: https://orcid.org/0000-0002-4669-5034)
- Gülden Paçacı Çetin
- İnsu Yılmaz (ORCID: https://orcid.org/0000-0001-6023-6291)
- Serpil Köylüce (ORCID: https://orcid.org/0000-0002-6755-9074)
- Bahar Arslan (ORCID: https://orcid.org/0000-0002-2786-8489)
- Elif Aktaş Yapıcı (ORCID: https://orcid.org/0000-0002-8351-6330)
- Serhat Şeker (ORCID: https://orcid.org/0000-0002-2852-6181)
- Hatice Eylül Bozkurt Yılmaz (ORCID: https://orcid.org/0000-0001-7499-8676)
Institutions
- Erciyes University (TR)
Publication Details
- Journal
- Tuberkuloz ve Toraks
- Published
- 2025-03-23
- DOI
- https://doi.org/10.5578/tt.2025011058
- Primary Topic
- Asthma and respiratory diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Erciyes Üniversitesi